Tag: Breast Cancer

SUMMARY: The FDA on June 24, 2026, approved IBRANCE® (Palbociclib) in combination with Trastuzumab, with or without Pertuzumab, and endocrine therapy for the maintenance treatment of adults with Hormone Receptor (HR)–positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 321,910 new cases of female breast cancer will be diagnosed in 2026, and about 42,140 women will die of the disease, largely due to metastatic recurrence.

Breast cancer remains a biologically heterogeneous disease, with approximately 70% of tumors expressing estrogen receptors (ER) and/or progesterone receptors (PR). Among patients with metastatic disease, HR–positive, HER2-negative tumors represent the most common subtype (60-70%). However, 15%–20% of primary breast cancers overexpress HER2, a historically aggressive phenotype. Hormone Receptor (HR)-positive, HER2-positive, breast cancer occurs in about 8% to 10% of all invasive breast cancer cases, creating a biologically distinct subgroup characterized by signaling interplay between the HER2 and Estrogen Receptor pathways.

For patients with HR-positive, HER2-positive metastatic breast cancer, the current first-line standard consists of induction chemotherapy combined with dual HER2 blockade (Trastuzumab-HERCEPTIN® and Pertuzumab-PERJETA®), followed by maintenance HER2-targeted therapy plus endocrine therapy. While this approach has significantly improved outcomes, resistance remains inevitable for most patients. Preclinical data have consistently demonstrated bidirectional crosstalk between HER2 and ER signaling, as well as persistent activation of the cyclin D1–CDK4/6 axis, which may drive resistance to both endocrine and HER2-directed therapies. These mechanistic insights provided the scientific rationale for evaluating triple pathway inhibition, simultaneous targeting of HER2, ER, and CDK4/6 in this population.

Biological Rationale for CDK4/6 Inhibition

Cyclin-Dependent Kinases 4 and 6 (CDK4/6) regulate orderly progression from the G1 to S phase of the cell cycle through phosphorylation of the retinoblastoma (RB) protein. Aberrant activation of this pathway is implicated in tumor proliferation and therapeutic resistance across multiple breast cancer subtypes, including HER2-positive disease.

Palbociclib (IBRANCE®), an oral selective CDK4/6 inhibitor, suppresses RB phosphorylation and arrests cell-cycle progression. Preclinical HER2-positive models have demonstrated that sustained cyclin D1–CDK4/6 activity contributes to resistance to HER2-targeted therapies, and dual inhibition of CDK4/6 and HER2 has shown synergistic antitumor effects. Early-phase clinical studies further suggested that combining CDK4/6 inhibition with HER2-directed and endocrine therapy was feasible and potentially additive in efficacy. These findings led to the Phase 3 PATINA trial.

The PATINA Trial: Study Design

PATINA was an open-label, randomized Phase 3 study evaluating whether adding Palbociclib to maintenance therapy could extend disease control in patients with HR-positive, HER2-positive metastatic breast cancer.

Eligibility and Treatment Approach

Patients were enrolled after completing 4 to 8 cycles of induction chemotherapy plus HER2-targeted therapy without disease progression. Key eligibility criteria included:

• HR positivity (≥1% nuclear staining by IHC)
• HER2 positivity (IHC 3+ or ISH amplification per ASCO/CAP guidelines)
• No prior systemic therapy for metastatic disease beyond induction
• A disease-free interval ≥6 months after prior adjuvant HER2 therapy

A total of 518 patients were randomized 1:1:

• Palbociclib arm (n=261): Maintenance HER2-targeted therapy + endocrine therapy + Palbociclib (125 mg orally, 21 days on/7 days off; dose reductions permitted)
• Standard arm (n=257): Maintenance HER2-targeted therapy + endocrine therapy

Baseline characteristics were balanced. The median age was 53.4 years; 99% were female; 61.8% were postmenopausal. Importantly, 54.4% had de novo metastatic disease. The Primary endpoint was investigator-assessed Progression-Free Survival (PFS). Secondary endpoints included Objective Response, clinical benefit, safety, and Overall Survival.

Efficacy Outcomes: A Meaningful Extension of Disease Control

At a median follow-up of 53.5 months, the addition of Palbociclib resulted in a statistically and clinically significant improvement in PFS. The median PFS was 44.3 months in the Palbociclib group and 29.1 months in the standard therapy group (HR=0.75; P=0.02). The estimated PFS rates favored the Palbociclib arm over standard therapy at all measured time points and was 84.9% versus 73.2% at 12 months, 65,2% versus 55.3% at 24 months, and 46.5% versus 38.3% at 48 months respectively.

The depth and durability of response were also enhanced:

• Confirmed response rate: 32.9% vs. 24.8%
• Complete response rate: 14.3% vs. 11.3%
• Median duration of confirmed response: 44.9 vs. 30.8 months

Importantly, when the induction phase is included, total first-line disease control in the Palbociclib arm extended beyond four years. Early mortality was uncommon, with 6-month Overall Survival exceeding 99% in both groups, reflecting favorable biology among patients who completed induction therapy.

The control arm’s median PFS of 29 months exceeded initial projections, likely reflecting mandated endocrine therapy use and the exclusion of patients who progressed during induction, factors that enriched the study population for more favorable disease biology.

Safety Profile

The safety findings were consistent with known toxicities of Palbociclib and HER2-targeted therapies. Neutropenia was the predominant toxicity and febrile neutropenia was rare. Grade 3 and Grade 4 adverse events were 79.7% and 10% in the Palbociclib group versus 30.6% and 3.6% in the standard therapy group.

Clinical Implications

The PATINA trial supports a paradigm shift in the maintenance setting for HR-positive, HER2-positive metastatic breast cancer. By targeting HER2, Estrogen Receptor signaling, and CDK4/6-mediated cell-cycle progression concurrently, this strategy addresses key resistance mechanisms.

Achieving a median PFS exceeding 44 months represents a meaningful advance in a disease subtype historically associated with aggressive biology. While antibody–drug conjugates and other potent HER2-directed agents remain appropriate for selected high-risk patients, this chemotherapy-sparing maintenance intensification strategy provides durable disease control in a substantial proportion of patients.

The open-label design and limited racial diversity are important considerations. Additional analyses evaluating patient-reported outcomes, biomarker correlates, and central nervous system outcomes are ongoing and may further refine patient selection.

Conclusion

The addition of Palbociclib to maintenance anti-HER2 and endocrine therapy significantly prolongs Progression-Free Survival in patients with HR-positive, HER2-positive advanced breast cancer, albeit with increased, but manageable, hematologic toxicity. Triple pathway inhibition targeting HER2, estrogen receptor, and CDK4/6 signaling may now represent a compelling first-line maintenance strategy capable of extending disease control beyond four years in appropriately selected patients.

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer. Metzger O, Mandrekar S, Goel S, et al. N Engl J Med 2026;394:451-462.

SUMMARY: The FDA on May 15, 2026, approved fam-Trastuzumab deruxtecan-nxki (T-DXd, ENHERTU®), followed by a taxane, Trastuzumab, and Pertuzumab (THP) for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. FDA also approved two companion diagnostic devices, the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the VENTANA HER2 Dual ISH DNA Probe Cocktail, both for identifying HER2-positive (IHC3+ or ISH+) patients for treatment with T-DXd, consistent with the approved drug labeling.

Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 321,910 new cases of female breast cancer will be diagnosed in 2026, and about 42,140 women will die of the disease, largely due to metastatic recurrence.

Human Epidermal growth factor Receptor 2–positive (HER2+) breast cancer accounts for approximately 15%-20% of all breast malignancies and historically has been associated with aggressive disease biology. Over the past decade, the integration of dual HER2 blockade with Trastuzumab (HERCEPTIN®) and Pertuzumab (PERJETA®) alongside cytotoxic chemotherapy has substantially improved outcomes. In patients with Stage II–III disease, neoadjuvant therapy has become the standard treatment approach, enabling early assessment of treatment response and guiding postoperative therapy.

The present FDA approval was based on DESTINY-Breast11 trial, which explored whether Antibody-Drug Conjugate (ADC)-based therapy, could improve efficacy, while reducing the toxicity burden associated with traditional Anthracycline and Carboplatin containing regimens.

Trial Design and Patient Population

DESTINY-Breast11 was a global, multicentre, open-label Phase III study conducted across 147 sites in 18 countries. The trial enrolled patients with high-risk, locally advanced, or inflammatory HER2-positive early-stage breast cancer, defined by lymph node-positive disease (N1-3) or primary tumors staged T3-4.

A total of 927 female patients were randomized across three treatment arms:

Patients assigned to the investigational combination arm received T-DXd 5.4 mg/kg intravenously every 3 weeks for four cycles followed by Paclitaxel 80 mg/m² weekly, Trastuzumab 6 mg/kg every 3 weeks and Pertuzumab 840 mg loading dose followed by 420 mg every 3 weeks for 4 cycles (T-DXd followed by THP; N=321)

The comparator arm received Dose-dense Doxorubicin 60 mg/m² every 2 weeks, Cyclophosphamide 600 mg/m² every 2 weeks for four cycles, followed by Paclitaxel 80 mg/m² weekly with concurrent Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg every 3 weeks Pertuzumab 840 mg loading dose, followed by 420 mg every 3 weeks for 4 cycles. (Dose-dense AC followed by THP (ddAC-THP; N=320)

The T-DXd monotherapy arm evaluated eight cycles of T-DXd at 5.4 mg/kg every 3 weeks; however, enrollment into this cohort was discontinued early following an Independent Data Monitoring Committee (IDMC) review (T-DXd monotherapy; N=286)

Median patient age was 50 years, 88% had an ECOG performance status of 0, and approximately 72% had Hormone Receptor (HR)-positive disease. HER2 expression was strongly positive in most patients, with 88% classified as IHC 3+.

Primary Endpoint Met with Significant pCR Improvement

The Primary endpoint was centrally assessed pathological Complete Response (pCR), defined as ypT0/is ypN0 following surgery.

Results demonstrated 67.3% pCR rate with T-DXd-THP vs 56.3% with ddAC-THP. This translated into an absolute improvement of 11% (95% CI: 4.0%-18.3%; P=0.003). Importantly, benefit was observed across hormone receptor subgroups:

• HR-positive disease: 61.4% vs 52.3%
• HR-negative disease: 83.1% vs 67.1%

The magnitude of benefit in the HR-negative cohort was particularly notable, with an absolute pCR improvement exceeding 16%. Investigators also reported improved Residual Cancer Burden (RCB) outcomes with T-DXd-THP, with RCB-0/I rates reaching 81.3% compared with 69.1% for the standard regimen.

Early EFS Signal and Safety Advantages

While Event-Free Survival (EFS) data remain immature, early findings favored the investigational approach. At 4.5% maturity, the Hazard Ratio for EFS comparing T-DXd-THP with ddAC-THP was 0.56 (95% CI: 0.26-1.17). Equally important for clinical practice, the ADC-based regimen demonstrated a more favorable toxicity profile than the anthracycline-containing comparator.

Grade ≥3 adverse events occurred in 37.5% of patients receiving T-DXd-THP vs 55.8% with ddAC-THP. Serious adverse events were also reduced and occurred in 10.6% with T-DXd-THP vs 20.2% with ddAC-THP. Cardiac toxicity rates were lower with the investigational regimen, with all-grade left ventricular dysfunction reported in only 1.3% of patients receiving T-DXd-THP compared with 6.1% in the ddAC-THP arm.

Given ongoing concerns regarding anthracycline-associated cardiotoxicity, these findings may be particularly relevant when selecting therapy for patients with baseline cardiovascular risk factors.

Interstitial lung disease (ILD)/pneumonitis, an established toxicity associated with T-DXd, was infrequent and comparable across treatment groups, occurring in approximately 4%-5% of patients. Three treatment-related deaths were reported overall.

Closure of the T-DXd Monotherapy Arm

Although the T-DXd monotherapy arm passed a predefined futility analysis, enrollment was halted early after IDMC review. Investigators cited multiple contributing factors, including lower pCR rates, reduced likelihood of superiority over standard therapy, and timing considerations surrounding surgery. Observed pCR rates were 43.0% with T-DXd alone, 67.3% with T-DXd-THP, and 56.3% with ddAC-THP. Interpretation of the monotherapy cohort was further complicated by protocol-directed transitions to local standard-of-care therapy after enrollment closure.

Clinical Implications

DESTINY-Breast11 introduces compelling evidence supporting ADC-based neoadjuvant therapy in high-risk HER2-positive early breast cancer. The combination of T-DXd followed by THP not only improved pCR rates compared with an anthracycline-based standard but also reduced severe toxicities and cardiac adverse events.

The findings are especially notable given the trial’s predominantly HR-positive and high-risk patient population, where pCR rates are historically more difficult to achieve. As clinicians continue to balance efficacy against long-term toxicity risks, DESTINY-Breast11 raises the possibility that Anthracycline- and Carboplatin-free regimens may emerge as a new treatment paradigm for selected patients with HER2-positive early-stage disease. Longer follow-up will be essential to determine whether the substantial pCR gains observed in DESTINY-Breast11 ultimately translate into durable improvements in Event-Free and Overall Survival.

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Harbeck N, Modi S, Pusztai L, et al., for the DESTINY-Breast11 Trial Investigators. Annals of Oncology, 2025; 37:166-179.

SUMMARY: The FDA on May 15, 2026, approved fam-Trastuzumab deruxtecan-nxki (T-DXd, ENHERTU®) for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with Trastuzumab (with or without Pertuzumab) and taxane-based treatment.

FDA also approved two companion diagnostic devices, the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the VENTANA HER2 Dual ISH DNA Probe Cocktail, both for identifying HER2-positive (IHC3+ or ISH+) patients for treatment with T-DXd, consistent with the approved drug labeling.

Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 321,910 new cases of female breast cancer will be diagnosed in 2026, and about 42,140 women will die of the disease, largely due to metastatic recurrence.

Background: Escalation Strategies in Residual Disease

The management of HER2-positive early breast cancer has undergone a profound transformation over the past two decades, driven by the integration of HER2-directed therapies across disease stages. In patients with Stage II–III disease, neoadjuvant therapy has become the standard treatment approach, enabling early assessment of treatment response and guiding postoperative therapy. Despite high rates of pathologic Complete Response (pCR) with contemporary neoadjuvant regimens, a clinically significant subset of patients exhibits residual invasive disease at surgery, an established marker of elevated recurrence risk.

The paradigm of risk-adapted postneoadjuvant therapy was firmly established by the KATHERINE trial, in which Trastuzumab emtansine (T-DM1-KADCYLA®) demonstrated a substantial improvement in Invasive Disease–Free Survival (IDFS) and Overall Survival (OS), compared with Trastuzumab alone. However, outcomes in higher-risk subgroups, particularly those with node-positive or extensive residual disease remain suboptimal, and CNS relapses continue to represent an unmet need.

Trastuzumab deruxtecan (T-DXd-ENHERTU®), a next-generation HER2-directed antibody–drug conjugate, has consistently demonstrated superior efficacy over T-DM1 in the metastatic setting, including activity in CNS disease. These data provided a strong rationale to evaluate whether T-DXd could further improve outcomes in the curative-intent, postneoadjuvant setting.

Trial Design and Patient Population

The present FDA approval was based on DESTINY-Breast05, which is a global, Phase III, open-label, randomized trial evaluating T-DXd versus T-DM1 in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy, enriched for high-risk features.

Eligible patients had:

• Residual invasive disease in breast and/or axillary nodes
• Either inoperable disease at presentation or node-positive disease after neoadjuvant therapy
• Prior receipt of standard neoadjuvant systemic therapy, including taxane-based chemotherapy and HER2-targeted therapy

A total of 1635 patients were randomized 1:1 to receive T-DXd (5.4 mg/kg) every 3 weeks (N=818) or T-DM1 (3.6 mg/kg) every 3 weeks (N=817) for up to 14 cycles. The Primary endpoint was invasive DFS (IDFS), with key Secondary endpoints including DFS, distant recurrence, CNS outcomes, and Overall Survival (OS). Notably, this trial enrolled a higher-risk population than prior studies: About 52% presented with inoperable disease at disease presentation, about 81% had node-positive disease after neoadjuvant therapy and approximately 79% received dual HER2 blockade preoperatively.

Efficacy: A New Benchmark for Invasive Disease–Free Survival

At a median follow-up of approximately 30 months, T-DXd demonstrated a clinically and statistically significant improvement in outcomes compared with T-DM1:

• • IDFS events or death: 6.2% (T-DXd) vs. 12.5% (T-DM1); Hazard ratio (HR): 0.47 (P<0.001)
  • 3-year IDFS: 92.4% vs. 83.7%
  • 3-year DFS: 92.3% vs. 83.5% (HR: 0.47)

The benefit was consistent across prespecified subgroups, including hormone receptor–positive disease driven largely by a reduction in distant recurrences, the dominant mode of failure. Importantly, the distant recurrence: 5.1% vs. 9.9% and CNS recurrence was numerically lower with T-DXd (2.1% vs. 3.1%)

Although Overall Survival data remain immature, the magnitude of IDFS improvement strongly supports a meaningful long-term benefit.

Safety Profile: Balancing Efficacy with Toxicity

The safety profiles of both agents were consistent with prior experience, though distinct in nature. The common adverse events with T-DXd included nausea (71%), neutropenia, vomiting and alopecia. Approximately 50% of patients had grade ≥3 adverse events. T-DM1 was associated with hepatotoxicity (elevated transaminases) and thrombocytopenia.

Key Safety Signal: Interstitial Lung Disease (ILD)

The most clinically significant toxicity associated with T-DXd remains ILD. The incidence was 9.6% (T-DXd) vs. 1.6% (T-DM1). They were mostly grade 1–2, but grade ≥3 events occurred and two treatment-related deaths reported. The trial incorporated proactive ILD monitoring, including serial low-dose chest CT imaging, enabling early detection. Importantly no increased ILD risk was observed with concurrent radiotherapy. Multidisciplinary evaluation is critical to distinguish ILD from radiation pneumonitis.

Clinical Context: Positioning Within Current Practice

These findings represent a clear evolution beyond the KATHERINE standard, particularly in a more contemporary, higher-risk population treated with modern neoadjuvant regimens.

Implications for Clinical Practice

• T-DXd emerges as the preferred postneoadjuvant therapy for patients with:
  • Residual invasive disease
  • Node-positive or otherwise high-risk features
• T-DM1 remains relevant for:
  • Lower-risk residual disease
  • Patients unable to tolerate T-DXd

Conclusions

DESTINY-Breast05 establishes Trastuzumab deruxtecan as a new standard of care in the postneoadjuvant management of high-risk HER2-positive early breast cancer with residual disease. The trial demonstrates a substantial and clinically meaningful improvement in Invasive Disease–Free Survival, a reduction in distant recurrence and manageable but clinically significant toxicity, particularly interstitial lung disease.

As the field moves toward increasingly personalized, response-adapted strategies, T-DXd represents a major advance, while underscoring the need for vigilant toxicity monitoring and multidisciplinary care in the curative setting.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. Loibl S, Park YH, Shao Z, et al. for the DESTINY-Breast05 Trial Investigators. N Engl J Med 2026;394:845-857.

SUMMARY: The FDA on May 1, 2026, approved Vepdegestrant (VEPPANU®), a heterobifunctional protein degrader, for adults with Estrogen Receptor (ER)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. FDA also approved the Guardant360 CDx as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with Vepdegestrant.

Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 316,950 new cases of female breast cancer will be diagnosed in 2025, and about 42,170 women will die of the disease, largely due to metastatic recurrence.

Background and Clinical Unmet Need
Approximately 70% of breast tumors express Estrogen Receptors and/or Progesterone Receptors. The most common subtype of metastatic breast cancer is Hormone Receptor-positive (HR-positive), HER2-negative breast cancer (65% of all metastatic breast tumors), and these patients are often treated with anti-estrogen therapy as first line treatment. However, resistance to hormonal therapy occurs in a majority of the patients, with a median Overall Survival (OS) of 36 months. With the development of Cyclin Dependent Kinases (CDK) 4/6 inhibitors, endocrine therapy plus a CDK4/6 inhibitor is the mainstay, for the management of ER+/HER2-negative metastatic breast cancer, as first line therapy. Even with this therapeutic combination, most patients will eventually experience disease progression, with up to 50% of patients acquiring ESR1 (Estrogen Receptor gene alpha) mutations after exposure to prior endocrine therapy in combination with CDK4/6 inhibitors. These mutations enable constitutive activation of the estrogen receptor, rendering tumors less responsive to traditional endocrine agents. Although Selective Estrogen Receptor Degraders (SERDs) such as Fulvestrant and Elacestrant are often used in this setting, their clinical activity is modest and limited by pharmacokinetic and mechanistic constraints, especially in heavily pretreated, endocrine-resistant disease.

A Novel Approach: Vepdegestrant and the PROTAC Platform
Vepdegestrant represents a first-in-class, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade the ER through direct engagement of the ubiquitin-proteasome system. Unlike traditional SERDs, which bind to and inactivate the ER before relying on indirect degradation pathways, Vepdegestrant forms a ternary complex between the ER and an E3 ubiquitin ligase. This results in efficient and targeted ubiquitination and subsequent degradation of the ER protein. Early-phase trials demonstrated that Vepdegestrant was well tolerated and exhibited promising antitumor activity in patients with heavily pretreated ER+/HER2-negative advanced breast cancer. This laid the foundation for VERITAC-2, the first Phase 3 study evaluating a PROTAC agent in oncology.

VERITAC-2: Study Design and Patient Population
Study Overview:
VERITAC-2 is a global, randomized Phase 3 trial comparing oral Vepdegestrant 200 mg once-daily continuously with Fulvestrant 500 mg intramuscularly days 1 and 15 of cycle 1 and day 1 of subsequent cycles, in postmenopausal women and men with ER+/HER2-negative advanced breast cancer, previously treated with a CDK4/6 inhibitor plus endocrine therapy. An additional line of endocrine therapy was permitted. However, patients previously exposed to SERDs or chemotherapy in the metastatic setting were excluded. A total of 624 patients (median age 60 years; 43%; N=270 with ESR1mutation tumors) were randomized 1:1 to receive Vepdegestrant (N=313) or Fulvestrant (N=311). Approximately 80% were postmenopausal, and 20% had received two prior lines of therapy in the advanced setting. Patients were stratified by ESR1 mutation status and presence of visceral disease. ESR1 mutational status was determined by blood circulating tumor DeoxyriboNucleic Acid (ctDNA) using central or local testing.

The Primary endpoint was Progression-Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR), first in the ESR1mutations subgroup and then in the overall population contingent on statistical assumptions. Secondary endpoints included Overall Survival (OS), Objective Response Rate (ORR), Clinical Benefit Rate (CBR), and Safety.

Key Efficacy Findings

In the ESR1-Mutant Population:

• Median PFS: 5.0 months with Vepdegestrant vs 2.1 months with Fulvestrant
• Hazard Ratio: 0.57 (95% CI, 0.42–0.77); P=0.0001
• 6-Month PFS Rate: 45.2% with Vepdegestrant vs 22.7% with Fulvestrant
• Objective Response Rate: 18.6% vs 4.0% (P=0.001)
• Clinical Benefit Rate: 42.1% vs 20.2% (P<0.001)

There was a 43% relative reduction in the risk of disease progression or death with Vepdegestrant compared with Fulvestrant. These results represent a statistically significant and clinically meaningful improvement in PFS and response outcomes among ESR1mutated patients, reinforcing the hypothesis that targeted ER degradation via PROTAC technology can overcome a key mechanism of endocrine resistance.

In the Overall Population:

• Median PFS: 3.7 months (Vepdegestrant) vs 3.6 months (Fulvestrant)
• HR: 0.83 (95% CI, 0.68–1.02); P=0.07

Although trends favored Vepdegestrant, the PFS difference in the unselected population did not reach statistical significance, underscoring the critical role of ESR1 mutation status as a biomarker of response to this agent.

Safety and Tolerability
Vepdegestrant was generally well tolerated, with most Adverse Events (AEs) being Grade 1 or 2. Grade 3 or more Treatment-Emergent AEs occurred in 23.4% receiving Vepdegestrant versus 17.6% with Fulvestrant. The most toxicities with Vepdegestrant were fatigue, elevated ALT/AST, nausea, vomiting and diarrhea. Discontinuation due to AEs occurred in only 2.9% of patients receiving Vepdegestrant. Importantly, gastrointestinal side effects, often limiting with oral SERDs, were infrequent and generally low-grade, reflecting the favorable tolerability of this novel agent.

Clinical Implications and Future Directions
The VERITAC-2 trial offers a landmark clinical validation for PROTACs in oncology. For patients with ER+/HER2-negative advanced breast cancer harboring ESR1 mutations, Vepdegestrant offers a statistically significant and clinically relevant advantage in Progression-Free Survival over Fulvestrant. The favorable safety profile, oral dosing convenience, and mechanistic novelty support its development as a next-generation standard of care in this biomarker-defined subgroup.

Although benefit was not observed in the all-comer population, the compelling results in ESR1mutated disease position Vepdegestrant as a precision endocrine therapy option that could reshape the treatment landscape. Ongoing investigations will clarify its role in earlier lines of therapy and in combination strategies, including with targeted or immunotherapeutic agents.

Conclusion
Vepdegestrant has emerged as a promising, targeted therapy for patients with ESR1-mutated ER+/HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor plus endocrine therapy. As the first PROTAC to reach Phase 3, its success in VERITAC-2 signals the clinical viability of targeted protein degradation platforms in hormone receptor–driven malignancies.

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. Campone M, De Laurentiis M, Jhaveri K, et al. for the VERITAC-2 Study Group. N Engl J Med. 2025;393:556-568.